Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

Giants fans surely don’t look back on cornerback Eli Apple’s tenure with New York very fondly. The 10th overall pick in the 2016 NFL Draft, solidly known as a draft bust amongst Giants fans ...

Eli Lilly stock has been a big-time winner over the last couple of years, but looming tariffs are worrying some investors. The pharmaceutical sector could be the next industry to face sweeping ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Tom Brady's playful rivalry with Eli Manning reignited after a viral video showed Brady joking about never losing to Manning, referencing their Super Bowl clashes. Giants fans swiftly responded ...

And Lilly just took a major step in the right direction. Did Eli Lilly just say checkmate to Novo Nordisk? Let's find out. So, first a quick bit about how this class of drugs works. Novo Nordisk's ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first ...

Drugmaker Eli Lilly (LLY 1.21%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...